Lotensin (benazepril hydrochloride) Tablets
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- May 2008
|The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.|
- Drug Interactions
- Carcinogenesis, Mutagenesis, Impairment of Fertility
- Frequent Urination
- The following adverse events of unknown frequency have been reported during post-marketing use of benazepril: small bowel angioedema, anaphylactoid reactions, hyperkalemia, agranulocytosis, and neutropenia.
Label approved 05/29/2008 is not available on Drugs@FDA
For current prescribing information, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682.